

CHAPTER ONE: INTRODUCTION.....	1
STUDY GOALS AND OBJECTIVES.....	1
REASONS FOR DOING THE STUDY	1
SCOPE AND FORMAT	1
INTENDED AUDIENCE.....	2
METHODOLOGY	2
RELATED BCC STUDIES	2
ANALYST CREDENTIALS.....	3
BCC ON-LINE SERVICES.....	3
DISCLAIMER	3
CHAPTER TWO: SUMMARY.....	4
SUMMARY.....	4
SUMMARY (CONTINUED)	5
<i>SUMMARY TABLE GLOBAL MARKET FOR PULMONARY DRUG</i>	
<i>DELIVERY TECHNOLOGIES, THROUGH 2016 (\$ MILLIONS)</i>	6
<i>SUMMARY FIGURE GLOBAL MARKET FOR PULMONARY DRUG</i>	
<i>DELIVERY TECHNOLOGIES, 2010–2016 (\$ MILLIONS)</i>	6
CHAPTER THREE: OVERVIEW	7
TECHNOLOGY TRENDS	7
PULMONARY DRUG DELIVERY	8
PULMONARY CONDITIONS AND THERAPIES.....	8
RESPIRATORY SYSTEM.....	9
Respiratory System (Continued).....	10
Lung	11
Particle Size, Toxicity and Drug Deposition.....	11
SYSTEMIC AND LOCAL THERAPY	12
Pulmonary Drug Delivery-Devices	13
Device Characteristics	13
Device Characteristics (Continued).....	14
Device Characteristics (Continued).....	15
Device Characteristics (Continued).....	16
Device Characteristics (Continued).....	17
Device Characteristics (Continued).....	18
Pulmonary Drug Delivery – the Future.....	19
Inhaler Devices	19
<i>TABLE 1 INHALER DEVICES AND CHARACTERISTICS</i>	19
<i>TABLE 2 DOSAGE FORMS-INHALERS</i>	20
Available Products.....	20
<i>TABLE 3 METERED DOSE INHALERS</i>	20
Available Products (Continued)	21
<i>TABLE 4 DRY POWDER INHALERS</i>	22
INHALER-DRUG PROFILES	22

Aerosol Aztreonam (Cayston).....	22
Dulera (mometasone furoate/formoterol fumarate dihydrate)	23
Amikacin	24
SYSTEMIC PULMONARY DELIVERY	25
Development of Exubera	25
Lung Cancer Concerns.....	26
Aerogen and Dance Pharmaceuticals	27
Safety Concerns	27
Future	27
Insulin -Exubera.....	28
MannKind's –Afrezza	29
Summary.....	30
Key Players	30
Pulmonary Drug Delivery-In a New Light.....	30
ASTHMA AND COPD – MAJOR RESPIRATORY DISEASE CONDITIONS	31
Asthma: Primary Respiratory Syndrome	31
Asthma: Primary Respiratory ... (Continued).....	32
Asthma and Obesity	33
<i>TABLE 5 ASTHMA AND BIOMARKERS</i>	34
Monitoring of Asthma.....	35
<i>TABLE 6 INHALED STEROIDS (ASTHMA INHALERS)</i>	36
<i>TABLE 7 SYSTEMIC STEROIDS FOR ASTHMA TREATMENT</i>	37
Delivery Methods.....	37
Delivery Methods (Continued)	38
Delivery Methods (Continued)	39
Chronic Obstructive Pulmonary Disease (COPD).....	40
What is COPD?	40
COPD and Causative Factors.....	41
<i>TABLE 8 COPD AND LUNG DAMAGE</i>	42
COPD and ... (Continued).....	43
Diagnosis of COPD.....	44
COPD and Treatment.....	45
Methods of Drug Delivery.....	46
METHODS OF DRUG DELIVERY	47
Aerosols	47
<i>TABLE 9 COPD DRUGS ON THE MARKET</i>	48
Formulations.....	49
INHALATION MARKET	49
Asthma Prevalence and Statistics	49
COPD and Incidence	50
Disease and Epidemiology.....	51

<i>TABLE 10 INHALED DRUGS AND MARKET OPPORTUNITIES: CURRENT MARKET FOR INHALED DRUGS (% MARKET SHARE)</i>	52
CHAPTER FOUR: PULMONARY DRUG DELIVERY SYSTEM	53
BENEFITS OF PULMONARY DRUG DELIVERY SYSTEMS.....	53
INHALER DEVICES	53
<i>TABLE 11 INHALER DEVICES</i>	54
Pulmonary Drug Delivery Technologies.....	54
Technology Descriptions.....	54
Wide Array of Applications	54
<i>TABLE 12 DRUGS AND THERAPEUTIC AGENTS ADMINISTERED BY INHALATION</i>	55
Types of Inhalation Devices	55
Inhalers	55
Metered-dose Inhalers.....	56
MDIs-How Does It Work?.....	56
History	57
MDIs and Drug Delivery	57
Advantages and Challenges for MDIs.....	58
MDIs and Corticosteroids.....	58
<i>TABLE 13 BRAND NAME METERED DOSE INHALERS (CORTICOSTEROIDS)</i>	59
Bronchodilators	59
<i>TABLE 14 BRAND NAME METERED DOSE INHALERS (BRONCHODILATORS)</i>	59
Combination Inhalers.....	59
Nonsteroidal Inhalers.....	60
Problems with MDI Use and Spacers	60
Problems with ...(Continued)	61
Propellants and MDI Development.....	62
<i>TABLE 15 LIST OF METERED DOSE INHALERS AND INGREDIENTS</i>	63
Fluticasone.....	63
Fluticasone and Salmeterol	64
Flunisolide.....	64
Beclomethasone	64
Transition to HFA propellants.....	65
Chlorofluorocarbons (CFCs)	65
<i>TABLE 16 THE SEVEN CFC INHALERS</i>	66
Analgesic Inhalers	66
Dry Powder Inhaler (DPI).....	67
Dry Powder ... (Continued)	68
<i>TABLE 17 TYPES OF DPI DEVICES</i>	69
Types of DPI Devices	69
<i>TABLE 18 DPIS CURRENTLY ON THE MARKET</i>	70
<i>TABLE 18 (CONTINUED)</i>	71

<i>TABLE 19 DPI: ADVANTAGES VERSUS DISADVANTAGES</i>	72
<i>TABLE 20 TYPES OF DRY POWDER INHALERS (DPI)</i>	72
DPIs for Children.....	72
Nebulizers.....	73
How Do They Work?	73
Use.....	74
<i>TABLE 21 NEBULIZERS AND DRUGS</i>	74
Use (Continued)	75
<i>TABLE 22 NEBULIZERS: ADVANTAGES AND DISADVANTAGES</i>	76
Ultrasonic Nebulizers	76
<i>TABLE 23 VIBRATING MESH NEBULIZERS</i>	77
Factors Influencing Clinical Effectiveness of Inhalation Devices.....	78
CONCLUSIONS.....	79
CHAPTER FIVE: PULMONARY DRUG DELIVERY: DRUGS IN USE.....	80
CURRENT INHALATION DRUGS AND MARKET.....	80
AEROSOL AZTREONAM (CAYSTON)	80
DULERA (MOMETASONE FUROATE/FORMOTEROL FUMARATE DIHYDRATE)	81
AMIKACIN	82
PULMONARY DELIVERY OF SYSTEMIC DRUGS.....	83
Antibiotics	83
Analgesics	83
Anti-emetics	83
<i>TABLE 24 THERAPEUTIC AGENTS ADMINISTERED BY INHALATION</i>	84
Pulmonary Specific Vasodilators	84
Nicotine	85
Nebulizers for Pediatric Care.....	85
Vaccines.....	85
Obesity	85
Drugs and Inhalers: How do they Work?	85
<i>TABLE 25 SHORT-ACTING BRONCHODILATOR INHALERS</i>	86
<i>TABLE 26 LONG-ACTING BRONCHODILATOR INHALERS</i>	86
Steroid Inhalers	87
<i>TABLE 27 INHALED STEROID MEDICATIONS</i>	87
<i>TABLE 28 COMBINATION INHALERS</i>	87
Breath-Activated Inhalers	88
Nebulizers	88
Pulmonary Delivery.....	89
Controlled Release.....	89
Controlled Release (Continued).....	90
Controlled Release (Continued).....	91
Formulations.....	92

Lactose Carrier Systems.....	92
Liposomes.....	93
Liposomes (Continued).....	94
PulmoSpheres.....	95
Biodegradable Polymers.....	96

CHAPTER SIX: GLOBAL MARKET FOR PULMONARY DRUG

DELIVERY TECHNOLOGIES.....	97
GLOBAL RESPIRATORY MARKET.....	97
DRUG DELIVERY MARKET.....	98
Drug Delivery Technologies and Market.....	98
GLOBAL PHARMACEUTICAL MARKET.....	99
TABLE 29 GLOBAL PHARMACEUTICAL SALES, THROUGH 2016 (\$	
BILLIONS).....	100
FIGURE 1 GLOBAL PHARMACEUTICAL SALES, 2010–2016 (\$	
BILLIONS).....	100
Pharmaceutical Growth Rates.....	101
A Shift to Generics as Patents Expire.....	101
Growth in New Drugs.....	101
Recent Mergers and Acquisitions (M&A Deals).....	102
Emerging Markets.....	103
United States Pharmaceutical Industry.....	104
Top 20 Pharmaceutical Companies.....	105
TABLE 30 TOP 20 PHARMACEUTICAL COMPANIES IN 2011 (\$	
MILLIONS).....	106
TABLE 30 (CONTINUED).....	107
TABLE 31 TOP 20 PHARMACEUTICAL COMPANIES IN 2010 (\$	
MILLIONS).....	107
TABLE 31 (CONTINUED).....	108
TABLE 32 TWELVE LARGEST PHARMACEUTICAL COMPANIES IN	
2010 (\$ MILLIONS).....	108
India and the Pharmaceutical Market.....	109
DRUG DELIVERY MARKET.....	109
Global Market.....	109
TABLE 33 TOTAL GLOBAL DRUG DELIVERY TECHNOLOGIES	
MARKET, THROUGH 2016 (\$ MILLIONS).....	110
FIGURE 2 TOTAL GLOBAL DRUG DELIVERY TECHNOLOGIES	
MARKET, 2010–2016 (\$ MILLIONS).....	111
TABLE 34 GLOBAL DRUG DELIVERY TECHNOLOGIES MARKET,	
THROUGH 2016 (\$ MILLIONS).....	111
FIGURE 3 GLOBAL DRUG DELIVERY TECHNOLOGIES MARKET,	
2010–2016 (\$ MILLIONS).....	112
Oral Drug Delivery.....	112
TABLE 35 GLOBAL ORAL DRUG DELIVERY TECHNOLOGIES	
MARKET, THROUGH 2016 (\$ MILLIONS).....	113

<i>FIGURE 4 GLOBAL ORAL DRUG DELIVERY TECHNOLOGIES MARKET, 2010–2016 (\$ MILLIONS)</i>	113
Implantable and Injectable Drug Delivery.....	114
<i>TABLE 36 GLOBAL IMPLANTABLE/INJECTABLE DRUG DELIVERY MARKET, THROUGH 2016 (\$ MILLIONS)</i>	114
<i>FIGURE 5 GLOBAL IMPLANTABLE/INJECTABLE DRUG DELIVERY MARKET, 2010–2016 (\$ MILLIONS)</i>	115
Transdermal Drug Delivery.....	116
<i>TABLE 37 GLOBAL TRANSDERMAL DRUG DELIVERY TECHNOLOGIES MARKET, THROUGH 2016 (\$ MILLIONS)</i>	116
<i>FIGURE 6 GLOBAL TRANSDERMAL DRUG DELIVERY TECHNOLOGIES MARKET, 2010–2016 (\$ MILLIONS)</i>	117
Drug Delivery Market in the U.S.	117
<i>TABLE 38 US DRUG DELIVERY TECHNOLOGIES MARKET, THROUGH 2015 (\$ MILLIONS)</i>	117
<i>FIGURE 7 US DRUG DELIVERY TECHNOLOGIES MARKET, 2010–2016 (\$ MILLIONS)</i>	118
Pulmonary Drug Delivery.....	118
<i>TABLE 39 TYPES OF INHALER UNITS SOLD WORLDWIDE, 2007 (%)</i>	119
<i>TABLE 40 GLOBAL PULMONARY DELIVERY TECHNOLOGIES MARKET, THROUGH 2016 (\$ MILLIONS)</i>	119
<i>FIGURE 8 GLOBAL PULMONARY DELIVERY TECHNOLOGIES MARKET, 2010–2016 (\$ MILLIONS)</i>	120
<i>TABLE 41 PULMONARY DELIVERY TECHNOLOGIES MARKET IN THE U.S. AND EUROPE, THROUGH 2016 (\$ MILLIONS)</i>	120
<i>FIGURE 9 PULMONARY DRUG DELIVERY TECHNOLOGIES MARKET IN THE U.S. AND EUROPE, 2010–2016 (\$ MILLIONS)</i>	121
PULMONARY DRUG DELIVERY SYSTEMS.....	122
Metered Dose Inhalers (MDIs).....	122
Leading Inhalation Prescription Drugs across All Segments.....	123
<i>TABLE 42 MARKET FOR MDI TECHNOLOGIES, THROUGH 2016 (\$ MILLIONS)</i>	124
<i>FIGURE 10 MARKET FOR MDI TECHNOLOGIES, 2010–2016 (\$ MILLIONS)</i>	125
Dry Powder Inhalation (DPI).....	125
<i>TABLE 43 MARKET FOR DPI TECHNOLOGIES, THROUGH 2016 (\$ MILLIONS)</i>	126
<i>FIGURE 11 MARKET FOR DPI TECHNOLOGIES, 2010–2016 (\$ MILLIONS)</i>	126
The Attractiveness of Inhalers.....	127
Phase-out of CFC inhalers and Future Developments.....	127
Phase-out of CFC ... (Continued).....	128
Phase-out of CFC ... (Continued).....	129

<i>TABLE 44 SALES OF INHALED STEROIDS AND AEROSOL BETA AGONISTS JANUARY TO JUNE 2007 (\$ MILLIONS/%)</i>	130
Dry Powder Inhalation: A Promising Technology	130
Dry Powder Inhalers	131
<i>TABLE 45 DPI DEVICES (BRAND NAME/MANUFACTURER)</i>	131
Growth for DPIs.....	132
<i>TABLE 46 GROWTH AREAS FOR INHALERS</i>	132
TOP SELLING INHALED DRUGS	132
Fluticasone/Salmeterol.....	133
Fluticasone/Salmeterol (Continued)	134
<i>TABLE 47 TOP SELLING INHALERS, 2010 (\$ MILLIONS)</i>	135
Tiotropium Bromide	135
Tiotropium Bromide (Continued).....	136
Tiotropium Bromide (Continued).....	137
Other Drugs	138
MAJOR PLAYERS	138
GlaxoSmithKline	138
<i>TABLE 48 TOP SELLING DRUGS IN 2010 (MILLIONS)</i>	138
Nebulizers: Displaying Promising Growth.....	139
<i>TABLE 49 GLOBAL RESPIRATORY DEVICE MARKET, THROUGH 2016 (\$ MILLIONS)</i>	139
<i>FIGURE 12 GLOBAL RESPIRATORY DEVICE MARKET, 2010–2016 (\$ MILLIONS)</i>	139
Nebulizers: Displaying ...(Continued)	140
<i>TABLE 50 U.S. RESPIRATORY DEVICE MARKET, THROUGH 2016 (\$ MILLIONS)</i>	141
<i>FIGURE 13 U.S. RESPIRATORY DEVICES MARKET, 2010–2016 (\$ MILLIONS)</i>	142
<i>TABLE 51 GLOBAL MARKET FOR NEBULIZERS, THROUGH 2016 (\$ MILLIONS)</i>	142
<i>FIGURE 14 GLOBAL MARKET FOR NEBULIZERS, 2010–2016 (\$ MILLIONS)</i>	143
Nebulizers on the Market.....	143
GLOBAL TRENDS AND INHALER MARKET	144
Asia.....	144
Asia (Continued)	145
Asia (Continued)	146
CHAPTER SEVEN: GLOBAL MARKET TRENDS	147
GLOBAL MARKET TRENDS	147
REGULATORY CHANGES –PULMONARY DRUG DELIVERY HURDLES.....	148
INCREASED RESEARCH AND DEVELOPMENT EFFORTS	148
AEROSOL DELIVERY MARKET	149
Distribution Channels	149

GROWTH AND NEW DEVELOPMENTS	150
Pulmonary Disease Drug Market	151
Market Trends in Asia	151
Market Segmentation.....	152
Patient Involvement	153
Pulmonary Insulin.....	154
Exubera	155
Afrezza.....	155
Inhaled Small Molecule Therapeutics	156
<i>TABLE 52 APPROVED PULMONARY DRUGS IN RECENT YEARS</i>	<i>156</i>
<i>TABLE 52 (CONTINUED).....</i>	<i>157</i>
SELECTED PROFILES OF NEW DRUGS ON THE MARKET	157
Dulera	157
Dulera (Continued)	158
Arcapta (indacaterol maleate inhalation powder).....	159
Daliresp.....	160
Daliresp (Continued)	161
CHAPTER EIGHT: KEY COMPANIES	162
KEY COMPANIES.....	162
3M	163
AKELA PHARMA INC (CANADA)	163
ALEXZA PHARMACEUTICALS.....	164
ALKERMES.....	164
ALPHARX INC.....	165
AOP ORPHAN PHARMACEUTICALS	165
APT PHARMACEUTICALS, INC.	166
ARADIGM CORPORATION (USA).....	166
ASTRAZENECA PLC (U.K.)	167
AXENTIS PHARMA.....	167
CONSORT MEDICAL PLC (UK)	168
DAIICHI SANKYO.....	168
DEY L.P. (USA)	169
GILEAD SCIENCES	169
GLAXOSMITHKLINE PLC (UK).....	169
GRACEWAY PHARMACEUTICALS, LLC (USA)	170
HOVIONE.....	170
INSPIRE PHARMACEUTICALS, INC.	171
MANNKIND	171
MAP PHARMACEUTICALS	172
MERCK & CO.....	173
MICRODOSE THERAPEUTX.....	173
MPEX PHARMACEUTICALS.....	173
NEKTAR THERAPEUTICS	174
NEXT SAFETY.....	175

NOVARTIS INTERNATIONAL AG	175
ORIEL THERAPEUTICS, INC.	175
PEARL THERAPEUTICS.....	176
PHARMAXIS	176
PULMATRIX	177
RESPIRICS.....	177
SAVARA.....	178
SKYEPHARMA PLC (UK).....	178
SUNOVION PHARMACEUTICALS INC.	179
SYNAIRGEN RESEARCH LTD	179
TEVA NORTH AMERICA	180
THERAVANCE	180
UNITED THERAPEUTICS	181
VECTURA GROUP PLC (UK).....	181
CHAPTER NINE: DEVELOPMENTS AND COLLABORATIONS	182
CURRENT AND FUTURE DEVELOPMENTS	182
BAYER SCHERING PHARMA AG, GERMANY.....	182
CIVITAS THERAPEUTICS.....	183
DR REDDY'S LABORATORIES.....	184
MANNKIND'S INHALED INSULIN DRUG AFREZZA.....	184
MannKind's Inhaled ... (Continued).....	185
PEARL THERAPEUTICS.....	186
PULMATRIX	187
RESPIRA THERAPEUTICS.....	187
SANDOZ	188
SUNPHARMA	189
TEVA.....	190
Teva (Continued)	191
THERAVANCE AND GLAXOSMITHKLINE.....	192
UNITED THERAPEUTICS CORPORATION	193
PRODUCTS IN CLINICAL DEVELOPMENT.....	194
FENTANYL TAIFUN	194
Fentanyl Taifun (Continued)	195
SPIRIVA RESPIMAT MIST INHALER.....	196
THERAVANCE PHASE III WITH RELOVAIR	197
Theravance Phase III with Relovair (Continued)	198
CHAPTER TEN: PATENT ANALYSIS	199
PATENT LANDSCAPE	199
REGULATORY ISSUES.....	200
NEW PATENT FILINGS.....	201
COMPETITIVE LANDSCAPE	202
<i>TABLE 53 AREAS FOR DRUG DELIVERY IMPROVEMENTS</i>	202
KEY PATENTS	202

Advair and Patent Issues	202
<i>TABLE 54 PULMONARY DRUG DELIVERY TECHNOLOGIES AND</i>	
<i>KEY PATENTS</i>	<i>203</i>
Advair and Patent Issues (Continued).....	204
Proventil HFA.....	205
REFERENCES	206
REFERENCES.....	206
REFERENCES (CONTINUED)	207